AzTrials
AzTrials

Pain, PerioperativeNCT06649604

Reducing Pain From Retinal Laser With Vibrational Stimulation

A study testing Vibration Anesthesia Device and Panretinal Photocoagulation in people with Pain, Perioperative, run by University of Alberta at 1 site in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to learn if Vibration Anesthesia Device works to reduce pain during retinal laser for diabetic retinopathy. The main question it aims to answer is: Does the Vibration Anesthesia Device reduces the pain felt by patients during the laser treatment? Researchers will compare the standard… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pain, Perioperative
What is being tested?
Vibration Anesthesia Device and Panretinal Photocoagulation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
50 participants
Where
1 siteCanada
Study dates
15 Oct 2026to 1 May 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Treatment naïve patients
  • Bilateral PRP for proliferative diabetic retinopathy required
  • >500 applications to each eye
  • < 51 applications difference between each eye, in the superior or inferior hemisphere.

Who cannot join

  • Poor pupil dilation < 5mm
  • Media opacity preventing laser

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Mathieu Carrière, MD, FRCSC contact

(780) 448-1801

mcarrie2@ualberta.ca

Canada1 site
  • Alberta Retina Consultant

    Edmonton, Alberta, T5H 0X5

    Mathieu Carrière, MD, FRCSC, (780) 448-1801, mcarrie2@ualberta.ca

Other trials in Canada

About this study

Official title: Alleviating Panretinal Photocoagulation Associated Ocular Pain With Vibratory Stimulation

The goal of this clinical trial is to learn if Vibration Anesthesia Device works to reduce pain during retinal laser for diabetic retinopathy. The main question it aims to answer is:

Does the Vibration Anesthesia Device reduces the pain felt by patients during the laser treatment? Researchers will compare the standard method (no vibration device) to the standard method with the Vibration Anesthesia Device to see if the device works to reduce discomfort during treatment.

Eligible participants will have both eyes treated as required, one eye with the device and the other one without. Both the side that will be treated with the device in place and the first side to be treated will be decided by random sequence.

Read the detailed description

Background:

Panretinal photocoagulation (PRP) is a widely used laser treatment for proliferative diabetic retinopathy (PDR). However, the associated ocular pain can make the procedure uncomfortable, leading to increased treatment visits or missed appointments. This pain is multifactorial and can be exacerbated by factors such as anxiety and hypervigilance. Traditional pain management techniques, such as regional anesthesia, are effective but invasive and carry potential complications. Oral medications have largely proven ineffective in alleviating PRP-related pain.

The Gate-Control Theory of pain posits that non-noxious stimuli can inhibit pain signals by activating A-β fibers, effectively "closing the gate" to pain transmission through A-δ and C fibers. The most relatable example is the mother rubbing a child's knee after an impact injury in the affected region. Transcutaneous electrical nerve stimulation (TENS) which utilizes the Gate-Control Theory of pain, has been shown to reduce ocular pain during PRP. However, its use raises practical concerns, including the need to carefully adjust pulse width, intensity, and frequency for effective pain relief. Additionally, some patients may find the muscular contractions or paresthesia uncomfortable. TENS is also contraindicated in individuals who are pregnant, have epilepsy, or have pacemakers. Vibratory stimulation activates cutaneous mechanoreceptors to reduce pain during intramuscular and subcutaneous injections. This technique is safer and less invasive than TENS and is therefore an ideal candidate for evaluating its effect in pain reduction during PRP. This study has the potential for an innovative concept by utilizing a vibratory device integrated within the PRP machine headrest.

Hypothesis:

Vibratory stimulation is expected to reduce ocular pain during PRP by activating cutaneous mechanoreceptors and inhibiting pain transmission, as suggested by the Gate-Control Theory. Its non-invasive nature makes it a practical alternative to traditional pain management methods, potentially enhancing patient comfort during the procedure.

Objective:

To evaluate the effectiveness of vibratory stimulation in reducing ocular pain during PRP treatments

Method:

Subjects will be recruited at a single tertiary referral center (Alberta Retina Consultants, Edmonton, Alberta). Matriculation will be established upon obtainment of consent, and patients will have the autonomy to withdraw from the study at any stage. The enrollment period will be from October 2024 to March 2025, with a total of 50 patients.

Laser settings will be tailored to each patient based on individual differences in pigmentation and tissue uptake. The threshold for treatment will be determined by observing an opacified photothermic response. For each patient, one eye will be treated without vibratory stimulation, while the contralateral eye will receive stimulation using the Blaine Labs Vibration Anesthesia Device. The assignment of which eye receives which treatment will be randomized using Python programming, ensuring a balanced allocation. To minimize variability, the time taken to perform PRP on both eyes will be kept as equal as possible. A no-treatment zone of 1 clock hour from the horizontal meridian will be maintained to avoid the long ciliary nerves. After treatment, patients will complete a validated survey based on the numeric rating scale (NRS) to assess pain levels for each eye treated.

Being tested
Vibration Anesthesia Device, Panretinal Photocoagulation
Keywords
Vibration Anesthesia Device, Perioperative Pain Alleviation, Panretinal Photocoagulation, Diabetic retinopathy treatment
Medical subject headings
Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vibration Anesthesia DeviceDevice

    The intervention arm of this study is distinguished by way of the use of the Vibration Anesthesia Device

  • Panretinal PhotocoagulationProcedure or surgery

    Laser treatment for diabetic retinopathy done in a standard fashion

Study groups in NCT06649604
Study groupRoleWhat they receive
PRP with the Vibration Anesthesia DeviceExperimentalLaser for PRP treatment as usual, but with the addition of the Vibration Device in one of the two eyes of a patient (The other eye receiving the same laser treatment without the device).
Receives: Device: Vibration Anesthesia Device; Procedure: Panretinal Photocoagulation
PRP without the Vibration Anesthesia DeviceActive comparatorLaser for PRP treatment as usual in one of the two eyes of a patient (other eye receiving the same treatment, but with the Vibration Device).
Receives: Procedure: Panretinal Photocoagulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pain Rating Scale

    Patient are enrolled on the same day as the study treatment. Patients will rate their pain sensation. They will have their first eye (left or right and with or without the Anesthesia Vibration Device based on randomization) treated, then they will assess their pain sensation. After this assessment, during the same session, their second eye will be treated and they will be asked to complete the same assessment for this second eye. The provided form to assess this outcome is a numeric scale from 0 (no pain) to 10 (worst possible pain) using the Wong-Baker Faces scale.

    Measured: At time of enrolment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Oct 2024
  2. Study start15 Oct 2026 (estimated)
  3. Primary completion1 Apr 2027 (estimated)
  4. Study completion1 May 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Crossover
Model description
All patient are their own control, using laser in both eyes, but only one using the Vibration Anesthesia Device.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06649604
Sponsor's protocol ID
Pro00144813
Status last verified
Oct 2025
First submitted
7 Oct 2024
Last updated
29 Oct 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Vibration Anesthesia Device and Panretinal Photocoagulation in people with Pain, Perioperative, run by University of Alberta at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 29 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mathieu Carrière, MD, FRCSC ((780) 448-1801, mcarrie2@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pain Rating Scale (time frame: At time of enrolment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in